CN113069475B - 一种细菌菌株及组合物和用途 - Google Patents
一种细菌菌株及组合物和用途 Download PDFInfo
- Publication number
- CN113069475B CN113069475B CN202110369840.5A CN202110369840A CN113069475B CN 113069475 B CN113069475 B CN 113069475B CN 202110369840 A CN202110369840 A CN 202110369840A CN 113069475 B CN113069475 B CN 113069475B
- Authority
- CN
- China
- Prior art keywords
- mno
- mice
- liver
- medicament
- senjun
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
试剂名称 | 每L培养基称取量 |
Trypticase peptone | 5g |
peptone | 5g |
Yeast extract | 10g |
Beef extract | 5g |
Glucose | 5g |
K2HPO4 | 2g |
Tween 80 | 1g |
Cysteine-HCl×H2O | 0.5g |
乙酸钠 | 2g |
5×盐溶液母液 | 8mL |
20×CaCl2溶液母液 | 2mL |
5×氯化血红素母液 | 2mL |
维生素K1母液 | 0.2mL |
脂肪酸 | MNO-863 | DSM22067 |
C9:0 FAME | 0.48 | 0 |
C11:0 ISO FAME | 27.50 | 2.89 |
C11:0 FAME | 0.33 | 1.31 |
C10:0 2OH FAME | 1.33 | 8.57 |
C12:0 FAME | 4.58 | 1.13 |
C13:0 ISO FAME | 1.58 | 0 |
C13:0 ANTEISO FAME | 3.30 | 2.35 |
C14:0 FAME | 25.01 | 13.03 |
C15:0 ISO FAME | 20.10 | 27.40 |
C15:0 ANTEISO FAME | 1.53 | 3.19 |
C15:0 ISO DMA | 0.60 | 0 |
C16:0 FAME | 9.34 | 21.14 |
C17:0 ISO FAME | 0.74 | 1.68 |
C18:0 FAME | 2.48 | 3.73 |
C19:0 CYC 9,10 DMA | 1.11 | 0 |
试剂名称 | 每升Buffer溶液称取量(g) |
KH2PO4 | 0.24 |
Na2HPO4 | 1.44 |
NaCl | 8.00 |
KCl | 0.20 |
Cysteine-HCl | 0.50 |
序号 | 组别 | 受试物/对照品 | 药物浓度 | 给药频率 | 动物数量 | 饲料 |
1 | NCD-control | PBS | / | 1次/天 | 8 | Normal diets |
2 | HFD-control | PBS | / | 1次/天 | 8 | D12492 |
3 | MNO-863 | MNH-863 | 1×1011CFU/mL | 1次/天 | 8 | D12492 |
分组 | 肝脏重量(g) |
NCD-control | 0.9875 |
HFD-control | 1.125 |
MNO-863 | 0.9325* |
序号 | 组别 | 受试物/对照品 | 荮物浓度 | 给药频率 | 动物数量 | 饲料 |
1 | NCD-control | PBS | / | 1次/天 | 8 | Normal diets |
2 | HFD-control | PBS | / | 1次/天 | 8 | D12492 |
3 | MNO-863 | MNH-863 | 1×1011CFU/mL | 1次/天 | 8 | D12492 |
4 | Liraglutide | Liraglutide | 40μg/ml | 1次/天 | 8 | D12492 |
分组 | 空腹血糖(mmol/L) |
NCD | 9.74±1.53* |
HFD | 11.81±2.82 |
MNO-863 | 6.74±1.28**** |
Liraglutide | 7.02±0.93**** |
分组 | HOMA-IR |
NCD | 1.74 |
HFD | 3.36 |
MNO-863 | 1.24 |
序号 | 组别 | 受试物/对照品 | 药物浓度 | 给药频率 | 动物数量 | 饲料 |
1 | NCD-control | PBS | / | 1次/天 | 8 | Normal diets |
2 | HFD-control | PBS | / | 1次/天 | 8 | D12492 |
3 | MNO-863 | MNH-863 | 1×1011CFU/mL | 1次/天 | 8 | D12492 |
4 | Liraglutide | Liraglutide | 40μg/ml | 1次/天 | 8 | D12492 |
Claims (12)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211741118.0A CN115998772A (zh) | 2021-04-06 | 2021-04-06 | 一种细菌菌株及组合物和用途 |
CN202110369840.5A CN113069475B (zh) | 2021-04-06 | 2021-04-06 | 一种细菌菌株及组合物和用途 |
AU2021439233A AU2021439233A1 (en) | 2021-04-06 | 2021-07-15 | Bacterial strain, composition, drug for use in combination and use |
PCT/CN2021/106579 WO2022213507A1 (zh) | 2021-04-06 | 2021-07-15 | 一种细菌菌株及组合物、联用药物和用途 |
EP21935727.4A EP4349350A1 (en) | 2021-04-06 | 2021-07-15 | Bacterial strain, composition, drug for use in combination, and use |
JP2023561061A JP2024513071A (ja) | 2021-04-06 | 2021-07-15 | 細菌株及び組成物、併用薬物と使用 |
CA3214687A CA3214687A1 (en) | 2021-04-06 | 2021-07-15 | Bacterial strain, composition, drug for use in combination and use |
KR1020237038125A KR20230167089A (ko) | 2021-04-06 | 2021-07-15 | 박테리아 균주 및 조성물, 병용 약물, 그리고 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110369840.5A CN113069475B (zh) | 2021-04-06 | 2021-04-06 | 一种细菌菌株及组合物和用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211741118.0A Division CN115998772A (zh) | 2021-04-06 | 2021-04-06 | 一种细菌菌株及组合物和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113069475A CN113069475A (zh) | 2021-07-06 |
CN113069475B true CN113069475B (zh) | 2023-06-02 |
Family
ID=76615273
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211741118.0A Pending CN115998772A (zh) | 2021-04-06 | 2021-04-06 | 一种细菌菌株及组合物和用途 |
CN202110369840.5A Active CN113069475B (zh) | 2021-04-06 | 2021-04-06 | 一种细菌菌株及组合物和用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211741118.0A Pending CN115998772A (zh) | 2021-04-06 | 2021-04-06 | 一种细菌菌株及组合物和用途 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN115998772A (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022213507A1 (zh) * | 2021-04-06 | 2022-10-13 | 慕恩(广州)生物科技有限公司 | 一种细菌菌株及组合物、联用药物和用途 |
CN114259507B (zh) * | 2021-12-27 | 2022-09-16 | 暨南大学 | 一种小克里斯滕森氏菌在制备治疗和/或预防高尿酸相关疾病的药物中的应用 |
CN115232774B (zh) * | 2022-08-05 | 2023-04-28 | 广东行海生物科技有限公司 | 一种医用细胞CMU-pb-7及其在制备抗氧化药物中的应用 |
CN116919994B (zh) * | 2023-09-15 | 2023-12-08 | 中国农业大学 | 小克里斯滕森氏菌在制备治疗多囊卵巢综合征的药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018162726A1 (fr) * | 2017-03-10 | 2018-09-13 | International Nutrition Research Company S.À.R.L | Bacteries specifiques pour leur utilisation comme medicament en particulier pour lutter contre le surpoids, l'obesite, les maladies cardiometaboliques et les maladies inflammatoires de l'intestin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015164555A1 (en) * | 2014-04-23 | 2015-10-29 | Cornell University | Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract |
WO2018045493A1 (zh) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | 克里斯坦森氏菌(Christensenella intestinihominis)及其应用 |
ES2763350B2 (es) * | 2018-11-28 | 2020-10-13 | Consejo Superior Investigacion | Cepa de christensenella minuta y uso de la misma |
MX2021010868A (es) * | 2019-03-11 | 2022-03-25 | Ysopia Biosciences | Bacteria de la familia christensenellaceaeas en la prevencion y/o tratamiento de enfermedades inflamatorias cronicas y/o enfermedades gastrointestinales inflamatorias y/o canceres. |
FR3099053B1 (fr) * | 2019-07-24 | 2023-01-20 | Inst Nat De La Rech Agronomique Inra | Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale |
CN113234602B (zh) * | 2021-04-01 | 2022-10-18 | 慕恩(广州)生物科技有限公司 | 一种球孢毛壳菌、菌剂、浸种液及应用 |
-
2021
- 2021-04-06 CN CN202211741118.0A patent/CN115998772A/zh active Pending
- 2021-04-06 CN CN202110369840.5A patent/CN113069475B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018162726A1 (fr) * | 2017-03-10 | 2018-09-13 | International Nutrition Research Company S.À.R.L | Bacteries specifiques pour leur utilisation comme medicament en particulier pour lutter contre le surpoids, l'obesite, les maladies cardiometaboliques et les maladies inflammatoires de l'intestin |
Also Published As
Publication number | Publication date |
---|---|
CN115998772A (zh) | 2023-04-25 |
CN113069475A (zh) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113069475B (zh) | 一种细菌菌株及组合物和用途 | |
KR102128287B1 (ko) | 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도 | |
US20220233639A1 (en) | Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria | |
KR102128289B1 (ko) | 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도 | |
CN116814464B (zh) | 一株发酵粘液乳杆菌jf5及其在制备减脂和助消化食品药品中的应用 | |
CN114181864A (zh) | 一种鼠李糖乳杆菌hf01及其应用 | |
CN115011532B (zh) | 一种副干酪乳杆菌jy062制剂及其制备方法和应用 | |
CN116083325B (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
CN117603828A (zh) | 一种具有降血糖和降血脂功能的鼠李糖乳酪杆菌LRa66及其应用 | |
CN116445346A (zh) | 一种改善多囊卵巢综合征的罗伊氏乳杆菌及其应用 | |
CN115074276A (zh) | 一株能够缓解非酒精性脂肪肝的普拉梭菌及其应用 | |
CN117085045A (zh) | 一种预防和/或治疗高尿酸血症的副干酪乳杆菌及其应用 | |
CN117343875A (zh) | 一株格氏乳杆菌my5及其在制备抗炎和通便护肠食品药品中的应用 | |
CN109874329B (zh) | 一种产丁酸栖粪杆菌及其培养方法和应用 | |
EP4349350A1 (en) | Bacterial strain, composition, drug for use in combination, and use | |
CN113388554A (zh) | 一株植物乳杆菌shy130及其缓解糖尿病的应用 | |
CN113604400B (zh) | 具有预防或治疗糖尿病作用的新型乳杆菌yuyingw | |
CN117363524B (zh) | 一株格氏乳杆菌my4及其在制备助睡眠和美白药品中的应用 | |
CN114606166B (zh) | 一株解木聚糖拟杆菌及其在制备酒精性肝病治疗或预防产品中的应用 | |
CN112592865B (zh) | 一株可保护肠道屏障的瘤胃乳杆菌及应用 | |
CN118620761A (zh) | 分离的克里斯滕森菌、包含其的组合物及用途 | |
CN117264808A (zh) | 一株普雷沃氏菌hf2130及其应用 | |
CN117965341A (zh) | 一株植物乳杆菌flp-215及其在溃疡性结肠炎、糖尿病和器官损伤中的应用 | |
CN116376739A (zh) | 一株具有降血脂功效的动物双歧杆菌乳亚种及其应用 | |
CN112076222A (zh) | 一种影响伊立替康所致小鼠腹泻和肠道菌群的富硒益生菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Lin Quansheng Inventor after: Zhang Tengxun Inventor after: Kuang Xiwen Inventor after: Tailihong Inventor after: Jiang Xianzhi Inventor after: Xian Yibo Inventor after: Kuang Zupeng Inventor after: Huang Baojia Inventor after: Kong Ping Inventor after: Deng Qianying Inventor after: Zhao Yingying Inventor after: Xiao Chen Inventor before: Lin Quansheng Inventor before: Kuang Xiwen Inventor before: Tailihong Inventor before: Jiang Xianzhi Inventor before: Kuang Zupeng Inventor before: Huang Baojia Inventor before: Kong Ping Inventor before: Deng Qianying Inventor before: Zhao Yingying Inventor before: Xiao Chen Inventor before: Zhang Tengxun |
|
GR01 | Patent grant | ||
GR01 | Patent grant |